+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Retinitis Pigmentosa Market by Type, Offering, End-use - Global Forecast 2025-2030- Product Image
Retinitis Pigmentosa Market by Type, Offering, End-use - Global Forecast 2025-2030- Product Image
Sale

Retinitis Pigmentosa Market by Type, Offering, End-use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967695
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Retinitis Pigmentosa Market grew from USD 9.85 billion in 2023 to USD 10.66 billion in 2024. It is expected to continue growing at a CAGR of 9.02%, reaching USD 18.04 billion by 2030.

Retinitis Pigmentosa (RP) is a group of rare, genetic disorders that affect the retina's ability to respond to light, leading to progressive vision loss. The global market for RP is majorly driven by the rising prevalence of genetic ocular diseases and increasing awareness about genetic testing, potentially enabling early detection and intervention. The necessity for effective treatments in the RP market is underscored by the currently limited therapeutic options, primarily focusing on symptom management, rather than a cure. Applications predominantly revolve around pharmaceuticals, gene therapies, and retinal implants. End-use demographics include hospitals, clinics, and research institutions keen on innovative interventions.

Key growth factors influencing the RP market include advancements in gene therapy, increasing research funding, and emerging biotechnological interventions. There's a significant opportunity in leveraging CRISPR technology and stem cell therapy to develop groundbreaking treatments that could modify disease progression. Additionally, partnerships between biotech firms and academic institutions could facilitate cutting-edge research outcomes. Companies can capitalize on these potential opportunities by investing in robust R&D pipelines and fostering collaborations for clinical trials, thereby gaining early accessibility to market innovations.

However, market growth faces challenges like high costs associated with treatment R&D, stringent regulatory approvals, and the complexity of genetic disorders which can impede therapy effectiveness. Furthermore, these treatments require rigorous clinical validation, posing risks of delayed adoption and financial unsustainability for smaller firms.

For business growth, innovative areas such as AI-guided retinal imaging technologies and precision medicine approaches offer promising avenues. These innovations could enhance diagnostic precision and facilitate personalized treatment regimens. The RP market is characterized by rapid technological advancements and necessitates a proactive approach for stakeholders to remain competitive. Continuous investment in biotechnology, coupled with strategic alliances, will be crucial for navigating the evolving landscape and capturing emerging markets, making it imperative for businesses to maintain agility and adaptability.

Understanding Market Dynamics in the Retinitis Pigmentosa Market

The Retinitis Pigmentosa Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of rare eye diseases affecting retina worldwide
    • Growing emphasis on genetic therapies and personalized medicine
  • Market Restraints
    • Accessibility and affordability of treatments required for retinitis pigmentosa
  • Market Opportunities
    • Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
    • Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
  • Market Challenges
    • Lack of awareness and misdiagnosis of the condition

Exploring Porter’s Five Forces for the Retinitis Pigmentosa Market

Porter’s Five Forces framework further strengthens the insights of the Retinitis Pigmentosa Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Retinitis Pigmentosa Market

External macro-environmental factors deeply influence the performance of the Retinitis Pigmentosa Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Retinitis Pigmentosa Market

The Retinitis Pigmentosa Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Retinitis Pigmentosa Market

The Retinitis Pigmentosa Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Retinitis Pigmentosa Market

The Retinitis Pigmentosa Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Retinitis Pigmentosa Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Astellas Pharma Inc., Beacon Therapeutics Limited, BIOGEN INC., Clino Corporation, Coave Therapeutics SA, Editas Medicine, Inc., GENSIGHT BIOLOGICS, Généthon, Johnson & Johnson Services, Inc., MeiraGTx Holdings PLC, Mimetogen Pharmaceuticals, Nacuity Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Oxford Biomedica PLC, Precision BioSciences, Inc., ProQR Therapeutics N.V., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Spark Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., and The Wyanoke Group.

Market Segmentation & Coverage

This research report categorizes the Retinitis Pigmentosa Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Autosomal Dominant Retinitis Pigmentosa
    • Autosomal Recessive Retinitis Pigmentosa
    • X-linked Retinitis Pigmentosa
  • Offering
    • Diagnosis
    • Treatment
  • End-use
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of rare eye diseases affecting retina worldwide
5.1.1.2. Growing emphasis on genetic therapies and personalized medicine
5.1.2. Restraints
5.1.2.1. Accessibility and affordability of treatments required for retinitis pigmentosa
5.1.3. Opportunities
5.1.3.1. Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
5.1.3.2. Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
5.1.4. Challenges
5.1.4.1. Lack of awareness and misdiagnosis of the condition
5.2. Market Segmentation Analysis
5.2.1. Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa
5.2.2. End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Retinitis Pigmentosa Market, by Type
6.1. Introduction
6.2. Autosomal Dominant Retinitis Pigmentosa
6.3. Autosomal Recessive Retinitis Pigmentosa
6.4. X-linked Retinitis Pigmentosa
7. Retinitis Pigmentosa Market, by Offering
7.1. Introduction
7.2. Diagnosis
7.3. Treatment
8. Retinitis Pigmentosa Market, by End-use
8.1. Introduction
8.2. Homecare
8.3. Hospitals
8.4. Specialty Clinics
9. Americas Retinitis Pigmentosa Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Retinitis Pigmentosa Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Retinitis Pigmentosa Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. jCyte's jCell Therapy Enters Phase 3 Trials for Retinitis Pigmentosa
12.3.2. Janssen Acquires Rights to Pioneering XLRP Gene Therapy from MeiraGTx, Catalyzing Advancements in Retinal Diseases
12.3.3. The RD Fund Backs NVasc's Breakthrough in Retinal Therapeutics
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. RETINITIS PIGMENTOSA MARKET RESEARCH PROCESS
FIGURE 2. RETINITIS PIGMENTOSA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. RETINITIS PIGMENTOSA MARKET DYNAMICS
FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
FIGURE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. RETINITIS PIGMENTOSA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 30. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 37. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 38. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 39. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 40. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 41. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 42. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 43. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 44. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 45. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 46. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 47. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 48. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 49. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 50. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 51. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 52. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 53. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 54. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 55. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 56. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 57. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 58. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 59. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 60. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 61. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 62. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 63. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 64. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 65. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 66. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 70. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 72. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 74. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 77. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 78. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 79. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 80. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 81. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 82. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 83. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 84. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 85. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 86. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 87. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 88. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 89. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 90. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 91. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 92. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 93. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 94. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 95. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 96. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 97. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 98. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 99. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 100. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 101. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 102. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 103. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 104. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 105. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 106. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 107. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 108. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 109. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 110. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 111. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 112. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 113. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 114. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 115. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 116. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 117. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 118. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 119. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 120. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 121. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 122. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 123. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 124. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 125. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 126. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 127. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 128. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 129. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 130. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 131. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 132. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 133. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 134. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 135. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 136. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 137. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 138. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 139. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 140. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 141. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 142. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 143. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 144. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 145. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 146. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 147. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 148. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 157. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 158. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 159. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 160. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 161. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 162. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 163. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 164. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 165. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 166. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 167. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 168. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 169. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 170. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 171. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 172. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 173. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 174. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 175. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 176. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 177. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 178. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 179. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 180. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 181. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 182. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 183. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 184. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 185. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 186. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 187. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 188. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 189. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 190. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 191. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 192. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 193. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 194. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 195. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 196. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 197. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 198. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 199. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 200. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 201. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 202. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 203. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 204. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 205. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 206. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 207. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 208. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 209. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 210. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 211. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 212. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 213. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 214. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 215. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 216. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 217. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 218. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 219. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 220. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 221. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 222. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 223. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 224. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 225. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 226. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 227. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 228. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 229. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 230. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 231. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 232. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 233. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 234. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 236. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 238. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 240. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 242. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 244. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 246. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 247. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 248. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 249. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 250. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 251. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 252. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 253. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 254. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 255. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 256. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 257. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 258. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 259. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 260. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 261. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 262. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 263. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 264. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 265. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 266. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 267. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 268. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 269. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 270. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 278. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 280. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
TABLE 282. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
TABLE 283. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Retinitis Pigmentosa market, which are profiled in this report, include:
  • 4D Molecular Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Beacon Therapeutics Limited
  • BIOGEN INC.
  • Clino Corporation
  • Coave Therapeutics SA
  • Editas Medicine, Inc.
  • GENSIGHT BIOLOGICS
  • Généthon
  • Johnson & Johnson Services, Inc.
  • MeiraGTx Holdings PLC
  • Mimetogen Pharmaceuticals
  • Nacuity Pharmaceuticals, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Oxford Biomedica PLC
  • Precision BioSciences, Inc.
  • ProQR Therapeutics N.V.
  • Sanofi S.A.
  • Santen Pharmaceutical Co., Ltd.
  • Spark Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • The Wyanoke Group

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 10.66 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.04 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Retinitis Pigmentosa Global Market Report 2024 - Product Image

Retinitis Pigmentosa Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
X-Linked Retinitis Pigmentosa (XLRP) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

X-Linked Retinitis Pigmentosa (XLRP) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Retinitis Pigmentosa Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Retinitis Pigmentosa Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 71 Pages
  • Global
From
Retinitis Pigmentosa Treatment Market Report and Forecast 2024-2032 - Product Image

Retinitis Pigmentosa Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Retinitis Pigmentosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Retinitis Pigmentosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 133 Pages
  • Global
From

About the Retinitis Pigmentosa Market

The Retinitis Pigmentosa (RP) market within the context of optical health pertains to the diagnosis, treatment, and management of this progressive genetic eye condition. Because RP leads to the degeneration of photoreceptor cells in the retina, culminating in vision loss, the market includes a variety of medical devices, therapeutic drugs, and supportive technologies. Advances in optogenetics, gene therapy, and electronic visual aids have pushed the boundaries of what can be offered to patients with this condition. Additionally, the development of specialized supplements that aim to preserve vision and the creation of assistive devices cater to the lifestyle needs of those affected. Specialists such as ophthalmologists and optometrists play key roles in managing the condition, which often necessitates a collaborative approach that includes genetic counselors and low-vision rehabilitation services. Several companies participate in the Retinitis Pigmentosa market, focusing on innovative solutions for managing and potentially treating this ocular disease. Spark Therapeutics is noted for its gene therapy research, while ProQR Therapeutics specializes in RNA-based treatments. Second Sight Medical Products develops implantable visual prosthetics, and OrCam creates advanced assistive technology devices that utilize artificial intelligence to assist those with visual impairments. These companies, among others, are at the forefront of efforts to improve the vision and quality of life for individuals affected by Retinitis Pigmentosa. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.